Course of Hyperkalemia in Patients on Hemodialysis.
Journal
International journal of nephrology
ISSN: 2090-214X
Titre abrégé: Int J Nephrol
Pays: United States
ID NLM: 101546753
Informations de publication
Date de publication:
2022
2022
Historique:
received:
18
11
2021
revised:
29
03
2022
accepted:
07
04
2022
entrez:
9
5
2022
pubmed:
10
5
2022
medline:
10
5
2022
Statut:
epublish
Résumé
Evidence of longitudinal serum potassium (sK These post hoc analyses of the placebo arm of the phase 3b DIALIZE study (NCT03303521) explored the course of hyperkalemia in hemodialysis patients receiving placebo. In DIALIZE, 196 patients receiving hemodialysis three times weekly were randomized to placebo or sodium zirconium cyclosilicate 5 g starting dose once daily on nondialysis days for 8 weeks. In these post hoc analyses of placebo patients overall ( In placebo patients, the mean predialysis sK Patients receiving placebo and hemodialysis maintained high predialysis sK
Sections du résumé
Background
UNASSIGNED
Evidence of longitudinal serum potassium (sK
Objective
UNASSIGNED
These post hoc analyses of the placebo arm of the phase 3b DIALIZE study (NCT03303521) explored the course of hyperkalemia in hemodialysis patients receiving placebo.
Methods
UNASSIGNED
In DIALIZE, 196 patients receiving hemodialysis three times weekly were randomized to placebo or sodium zirconium cyclosilicate 5 g starting dose once daily on nondialysis days for 8 weeks. In these post hoc analyses of placebo patients overall (
Results
UNASSIGNED
In placebo patients, the mean predialysis sK
Conclusions
UNASSIGNED
Patients receiving placebo and hemodialysis maintained high predialysis sK
Identifiants
pubmed: 35531468
doi: 10.1155/2022/6304571
pmc: PMC9071981
doi:
Types de publication
Journal Article
Langues
eng
Pagination
6304571Informations de copyright
Copyright © 2022 Bruce Spinowitz et al.
Déclaration de conflit d'intérêts
BS received research grants, lecture fees, and/or consulting fees from AstraZeneca, Akebia, Reata Pharmaceuticals, and Fresenius Medical Care. SF received research support and consulting fees from AstraZeneca. MFu received consulting fees and lecture fees from AstraZeneca Japan. MFo received travel support from Amgen and AstraZeneca and is an advisory board member for AstraZeneca. NG is an employee of AstraZeneca. AR received research or travel support from, and/or is a speaker, consultant, or advisory board member for AstraZeneca, Vifor Pharma, Fresenius Medical Care, Sanofi, Kadmon, Amag, Otsuka, Genzyme, GlaxoSmithKline, Omeros, Janssen, Reata Pharmaceuticals, Ironwood, and Amgen.
Références
J Am Soc Nephrol. 2017 Dec;28(12):3441-3451
pubmed: 28993507
Clin J Am Soc Nephrol. 2007 Sep;2(5):999-1007
pubmed: 17702709
Am J Nephrol. 2016;44(5):404-410
pubmed: 27784004
Nephrol Dial Transplant. 2009 Aug;24(8):2529-36
pubmed: 19293137
Nephrol Dial Transplant. 2017 Dec 01;32(12):2112-2118
pubmed: 28460113
J Nephrol. 2019 Aug;32(4):499-516
pubmed: 31119681
Am J Kidney Dis. 2015 Nov;66(5):884-930
pubmed: 26498416
Kidney Int Rep. 2018 Oct 29;4(2):301-309
pubmed: 30775627
J Am Soc Nephrol. 2019 Sep;30(9):1723-1733
pubmed: 31201218
PLoS One. 2019 Jun 21;14(6):e0218739
pubmed: 31226134
Hippokratia. 2010 Jul;14(3):193-7
pubmed: 20981169
Int J Cardiol. 2017 Oct 15;245:277-284
pubmed: 28735756
Nephrol Dial Transplant. 1997 Aug;12(8):1629-34
pubmed: 9269640
Nephrol Dial Transplant. 2018 Sep 1;33(9):1610-1620
pubmed: 29177463
Am J Nephrol. 2016;44(3):179-86
pubmed: 27592170
BMC Nephrol. 2019 Mar 6;20(1):85
pubmed: 30841854
Am J Kidney Dis. 2017 Feb;69(2):266-277
pubmed: 27866964
Kidney Int. 2011 Jan;79(2):218-27
pubmed: 20811332
Arch Intern Med. 2009 Jun 22;169(12):1156-62
pubmed: 19546417
Kidney Int Rep. 2019 May 30;4(9):1248-1260
pubmed: 31517144
Am J Kidney Dis. 2017 Jul;70(1):21-29
pubmed: 28111027